Nicholas Saraceno

Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.

For manufacturers who participate in the 340B program, costs have increased because they are required to provide steep discounts on their drugs at levels far below private market prices.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.

Dozens of companies are selling stem cell treatments and exosome therapies that have not been approved for use or authorized for emergency use by the FDA.